QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
Log in

LON:FARNFaron Pharmaceuticals Oy Share Price, Forecast & News

GBX 422.50
-12.50 (-2.87 %)
(As of 08/7/2020 11:03 AM ET)
Add
Compare
Today's Range
412.50
Now: GBX 422.50
435
50-Day Range
287.50
MA: GBX 358.35
480
52-Week Range
3.01
Now: GBX 422.50
595
Volume49,965 shs
Average Volume14,501 shs
Market Capitalization£197.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It also develops Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Read More
Faron Pharmaceuticals Oy logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+358-2-4695151

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueGBX 25.10 per share

Profitability

Miscellaneous

Employees18
Market Cap£197.73 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 422.50
-12.50 (-2.87 %)
(As of 08/7/2020 11:03 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FARN News and Ratings via Email

Sign-up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Faron Pharmaceuticals Oy (LON:FARN) Frequently Asked Questions

How has Faron Pharmaceuticals Oy's stock been impacted by COVID-19 (Coronavirus)?

Faron Pharmaceuticals Oy's stock was trading at GBX 297.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FARN stock has increased by 42.0% and is now trading at GBX 422.50.
View which stocks have been most impacted by Coronavirus
.

Has Faron Pharmaceuticals Oy been receiving favorable news coverage?

Media coverage about FARN stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Faron Pharmaceuticals Oy earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Faron Pharmaceuticals Oy
.

Who are some of Faron Pharmaceuticals Oy's key competitors?

What other stocks do shareholders of Faron Pharmaceuticals Oy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group (HZD), Celgene (CELG), Acura Pharmaceuticals (ACUR), Alphabet (GOOG), Northwest Pipe (NWPX), TriQuint Semiconductor (TQNT), Allstate (ALL), Allergy Therapeutics (AGY), Argentex Group (AGFX) and Alpha FX Group (AFX).

Who are Faron Pharmaceuticals Oy's key executives?

Faron Pharmaceuticals Oy's management team includes the following people:
  • Mr. Yrjö Erik Kristian Wichmann, CFO & Exec. Director (Age 61)
  • Dr. Juho Markku Jalkanen, Chief Devel. Officer (Age 41)
  • Dr. Markku Tapani Jalkanen Ph.D., Founder, CEO & Exec. Director (Age 64)
  • Dr. Mikael Maksimow Ph.D., VP of Operations (Age 43)
  • Dr. Matti Karvonen, Chief Medical Officer & VP of Drug Devel.

What is Faron Pharmaceuticals Oy's stock symbol?

Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN."

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Faron Pharmaceuticals Oy's stock price today?

One share of FARN stock can currently be purchased for approximately GBX 422.50.

How big of a company is Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy has a market capitalization of £197.73 million. Faron Pharmaceuticals Oy employs 18 workers across the globe.

What is Faron Pharmaceuticals Oy's official website?

The official website for Faron Pharmaceuticals Oy is www.faron.com.

How can I contact Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.